2.33

0.34% -0.008

Xortx Therapeutics Inc (XRTX)

Overview News Price History Discussions Forecast Stock Split

Xortx Therapeutics Inc stock is traded at $2.33, with a volume of 5,223. It is down -0.34% in the last 24 hours and up +9.91% over the past month. XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Previous Close:

$2.338

Open:

$2.18

24h Volume:

5,223

Relative Volume:

0.33

Market Cap:

$4.21M

Revenue:

Net Income/Loss:

$-2.77M

P/E Ratio:

-0.8804

EPS:

-2.6464

Net Cash Flow:

$-2.69M

1W Performance:

+3.10%

1M Performance:

+9.91%

6M Performance:

+13.66%

1Y Performance:

-42.07%

1-Day Range:

$2.18

$2.34

1-Week Range:

$2.16

$2.64

52-Week Range:

$1.725

$7.05

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Name

Xortx Therapeutics Inc

Sector

Healthcare (1083)

Industry

Biotechnology (602)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

XRTX's Discussions on Twitter

Compare XRTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XRTX Xortx Therapeutics Inc	2.32	3.67M	0	-2.77M	-2.69M	-2.6464
VRTX Vertex Pharmaceuticals Inc	546.91	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	810.84	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,030.86	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	141.91	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.68	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Xortx Therapeutics Inc Stock (XRTX) Latest News

Aug 17, 2026

XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks

Aug 17, 2026

Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan

Aug 17, 2026

Aug 15, 2026

XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 15, 2026

Aug 13, 2026

XORTX Therapeutics (XRTX) Advances 5.28% as Shares Test Resistance at $2.38Institutional Sentiment - vinanet.vn

Aug 13, 2026

Aug 12, 2026

XORTX (XRTX) Q1 2024 Earnings: Loss of -$1.24 per Share Misses Consensus by 372.2%Earnings Revision Upgrade - vinanet.vn

Aug 12, 2026

Aug 05, 2026

XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail

Aug 05, 2026

XORTX Therapeutics (XRTX) Edges Higher at $2.21 as Shares Hold Mid-Range PositionModified Schiff - vinanet.vn

Aug 05, 2026

Aug 04, 2026

Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan

Aug 04, 2026

Aug 02, 2026

XORTX Therapeutics (XRTX) Climbs 4.92% as Shares Approach Key Resistance at $2.23Fibonacci Retracement - dars.gov.et

Aug 02, 2026

Aug 01, 2026

XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et

Aug 01, 2026

Jul 31, 2026

XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com

Jul 31, 2026

XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan

Jul 31, 2026

Jul 29, 2026

XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks

Jul 29, 2026

XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan

Jul 29, 2026

XORTX Appoints New Director - GlobeNewswire

Jul 29, 2026

XORTX Board Gains Director With Over 20 Years in Financial Services - Stock Titan

Jul 29, 2026

Jul 28, 2026

XORTX Therapeutics, Inc. Revenue Breakdown – TSXV:XRTX - TradingView

Jul 28, 2026

Vectus Biosystems Appoints Dr Tara Speranza as CEO and CTO, Raises $791,000 to Accelerate VB0004 Clinical Development - Kalkine

Jul 28, 2026

Jul 27, 2026

Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome

Jul 27, 2026